TABLE 1.
Agents Currently under Investigation for the Treatment of Recurrent, Persistent, and Metastatic Cervical Cancer
| Target | Phase of Study | Agent(s) | Clinical Trials No. |
|---|---|---|---|
| Immunotherapy | |||
| CTLA | II | Ipilumimab | NCT01693783 |
| PD-1 | II | Nivolomab | NCT02257528 |
| TiLs | TiLs | NCT01585428 | |
| T-cell immunotherapy | HPV16 only | T cells | NCT02280811 |
| Pathway-Targeted Therapy | |||
| RAS/ERK/PI3K/AKT/MTOR | II | Trametanib (MEK inhibitor)/GSK2141795 (AKT inhibitor) | NCT01958112 |
| PI3K | II | BKM120 | NCT01613677 |
| RTK/Angiogenesis | II | Pazopanib/topotecan | NCT02348398 |
| RTK/Angiogenesis | II | Carboplatin/paclitaxel ± nintedanib or placebo followed by maintenance |
NCT02009579 |
| HPV-Related Therapy | |||
| HPV 16 and 18-positive cancer | II | VGX-3100 (plasmids encoding E6 and E7 protein)/INO-9012 (plasmid encoding interleukin 2) delivered via electroporation |
NCT01693783 |
| Therapeutic vaccine | I-II | ADXS11-001 high dose (therapeutic vaccine) | NCT02164461 |
| I-II | |||
| HPV 16 only | ISA101 (HPV 16 E6/E7 long peptides vaccine) with or without interferon alpha with carboplatin paclitaxel |
NCT02128126 | |
| Cytotoxic Agents | II | Albumin-bound paclitaxel/nedaplatin | NCT01667211 |
| II | Eribulin mesylate | NCT0167818 | |
| Other | |||
| Chromosome Region 1 Maintenance Protein | II | Selinexor | NCT02025985 |
Abbreviations: TiLs, tumor-infiltrating lymphocytes; HPV, human papillomavirus.
Studies are single arm unless otherwise indicated.